Precision Biosciences INC
SEC CIK 1357874 · DTIL · last insider filing 2026-06-05
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Germano Geno J | Director | filed 2020 - 2026 |
| Brown Melinda | Director | filed 2022 - 2026 |
| Buehler Kevin | Director | filed 2019 - 2026 |
| Frankel Stanley | Director | filed 2021 - 2026 |
| Pire Shari Lisa | Director | filed 2021 - 2026 |
| Amoroso Michael | Director · President and CEO | filed 2021 - 2026 |
| Wadsworth Samuel C. | Director | filed 2021 - 2024 |
| Jantz Derek | Director · Chief Scientific Officer | filed 2019 - 2022 |
| Schinazi Raymond F | Director | filed 2019 - 2022 |
| Kane Matthew R. | Director · President and CEO | filed 2019 - 2021 |
| Sharp Shalini | Director | filed 2019 - 2021 |
| YAO Tony Dung Ling | Director | filed 2019 - 2019 |
| Adelman Robert J | Director | filed 2019 - 2019 |
| Venbio Global Strategic Fund, L.P. | Director | filed 2019 - 2019 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Kelly John Alexander | Interim CFO | filed 2021 - 2026 |
| Smith J. Jefferson | Chief Research Officer | filed 2019 - 2026 |
| Scimeca Dario | General Counsel and Secretary | filed 2019 - 2026 |
| List Alan | Chief Medical Officer | filed 2021 - 2024 |
| Barton Shane | VP & Corporate Controller | filed 2021 - 2023 |
| Thomson David S. | Chief Operating Officer | filed 2019 - 2021 |
| Khazi Fayaz | CEO of Elo Life Systems | filed 2019 - 2021 |
| Ansari Abid | Chief Financial Officer | filed 2019 - 2020 |
| Heery Christopher | Chief Medical Officer | filed 2019 - 2020 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.